Stryker trades at 13% discount with strong growth and dividends in medtech sector

Stryker Corporation presents a strong investment opportunity in the medical technology sector, trading at a 13% discount to its fair value. The company benefits from robust industry growth and an innovation-driven strategy, with expected adjusted diluted EPS growth of 11.2% annually through 2028. This supports high single-digit dividend growth, making it attractive for income-focused investors. Key risks include cybersecurity threats and intense competition, but Stryker's diversified portfolio and disciplined capital management support a positive long-term outlook.